Maze Therapeutics, Inc. Common Stock

Price Chart

Risk-Adjusted Performance

Maze Therapeutics, Inc. Common Stock (MAZE) Price Performance

Maze Therapeutics, Inc. Common Stock (MAZE) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $49.00, up 2.02% from the previous close.

Over the past year, MAZE has traded between a low of $7.57 and a high of $50.44. The stock has gained 355.4% over this period. It is currently 547.3% above its 52-week low.

Maze Therapeutics, Inc. Common Stock has a market capitalization of $2.36B.

About Maze Therapeutics, Inc. Common Stock

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.